ONCT
Income statement / Annual
Last year (2023), Oncternal Therapeutics, Inc.'s total revenue was $785,000.00,
a decrease of 47.32% from the previous year.
In 2023, Oncternal Therapeutics, Inc.'s net income was -$39.48 M.
See Oncternal Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$785,000.00
|
$1.49 M
|
$4.32 M
|
$3.38 M
|
$2.43 M
|
$2.52 M
|
$1.67 M
|
-$2.51 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$29.75 M |
$179,000.00 |
$169,000.00 |
$12.00 M |
$10.16 M |
$46,000.00 |
$47,000.00 |
$2.51 M |
$43,000.00 |
$0.00 |
| Gross Profit |
-$28.97 M |
$1.31 M |
$4.15 M |
-$8.63 M |
-$7.73 M |
$2.48 M |
$1.63 M |
-$5.02 M |
-$43,000.00 |
$0.00 |
| Gross Profit Ratio |
-36.9 |
0.88 |
0.96 |
-2.56 |
-3.19 |
0.98 |
0.97 |
2 |
0 |
0 |
| Research and Development
Expenses |
$29.75 M
|
$32.98 M
|
$24.09 M
|
$12.54 M
|
$10.16 M
|
$29.67 M
|
$21.47 M
|
$17.23 M
|
$13.61 M
|
$20.87 M
|
| General & Administrative
Expenses |
$12.75 M
|
$13.46 M
|
$11.60 M
|
$8.37 M
|
$7.29 M
|
$9.39 M
|
$9.19 M
|
$8.71 M
|
$8.23 M
|
$9.48 M
|
| Selling & Marketing
Expenses |
$200,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.75 M
|
$13.46 M
|
$11.60 M
|
$8.37 M
|
$7.29 M
|
$9.39 M
|
$9.19 M
|
$8.71 M
|
$8.23 M
|
$9.48 M
|
| Other Expenses |
-$29.75 M |
-$1.49 M |
-$4.32 M |
-$3.38 M |
-$2.43 M |
$641,000.00 |
$216,000.00 |
$46,000.00 |
$57,000.00 |
-$259,000.00 |
| Operating Expenses |
$12.75 M |
$44.95 M |
$31.37 M |
$17.54 M |
$15.02 M |
$39.06 M |
$30.66 M |
$25.93 M |
$21.84 M |
$30.35 M |
| Cost And Expenses |
$42.50 M |
$44.95 M |
$31.37 M |
$17.54 M |
$15.02 M |
$39.06 M |
$30.66 M |
$25.93 M |
$21.84 M |
$30.35 M |
| Interest Income |
$2.24 M |
$777,000.00 |
$33,000.00 |
$16,000.00 |
$188,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$41.71 M
|
$179,000.00
|
$169,000.00
|
$150,000.00
|
$15.02 M
|
$7.59 M
|
$47,000.00
|
$28,000.00
|
$43,000.00
|
$102,000.00
|
| EBITDA |
$2.24 M
|
-$44.95 M
|
-$31.37 M
|
-$17.54 M
|
-$33.11 M
|
$1.01 M
|
-$30.39 M
|
-$17.70 M
|
-$18.66 M
|
-$39.31 M
|
| EBITDA Ratio |
2.85 |
-30.17 |
-7.27 |
-5.2 |
-6.12 |
-15.48 |
-18.31 |
13.58 |
0 |
0 |
| Operating Income Ratio
|
-53.14
|
-30.17
|
-7.27
|
-5.2
|
-13.65
|
-15.49
|
-18.31
|
10.33
|
0
|
0
|
| Total Other
Income/Expenses Net |
$2.24 M
|
$777,000.00
|
$33,000.00
|
$317,000.00
|
-$1.08 M
|
$1.01 M
|
$216,000.00
|
$8.21 M
|
$3.14 M
|
-$9.06 M
|
| Income Before Tax |
-$39.48 M |
-$44.17 M |
-$31.33 M |
-$17.23 M |
-$34.19 M |
-$38.42 M |
-$30.44 M |
-$17.72 M |
-$18.70 M |
-$39.41 M |
| Income Before Tax Ratio
|
-50.29
|
-29.64
|
-7.26
|
-5.1
|
-14.1
|
-15.24
|
-18.18
|
7.06
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$777,000.00 |
-$33,000.00 |
-$16,000.00 |
-$18.28 M |
$641,000.00 |
-$47,000.00 |
-$8.19 M |
-$3.12 M |
$8.70 M |
| Net Income |
-$39.48 M |
-$43.39 M |
-$31.30 M |
-$17.21 M |
-$15.91 M |
-$38.42 M |
-$30.44 M |
-$17.72 M |
-$18.70 M |
-$39.41 M |
| Net Income Ratio |
-50.29 |
-29.12 |
-7.25 |
-5.1 |
-6.56 |
-15.24 |
-18.18 |
7.06 |
0 |
0 |
| EPS |
-13.43 |
-16.5 |
-12.69 |
-16.95 |
-30.81 |
-11.52 |
-12.22 |
-8.52 |
-9.33 |
-33.72 |
| EPS Diluted |
-13.43 |
-16.5 |
-12.69 |
-16.95 |
-30.81 |
-11.52 |
-12.22 |
-8.52 |
-8.86 |
-33.72 |
| Weighted Average Shares
Out |
$2.94 M
|
$2.63 M
|
$2.47 M
|
$1.02 M
|
$516,449.00
|
$3.34 M
|
$2.49 M
|
$2.08 M
|
$2.01 M
|
$1.17 M
|
| Weighted Average Shares
Out Diluted |
$2.94 M
|
$2.63 M
|
$2.47 M
|
$1.02 M
|
$516,449.00
|
$3.34 M
|
$2.49 M
|
$2.08 M
|
$2.11 M
|
$1.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
